Spectrum Pharmaceuticals (NASDAQ:SPPI), Immunocore Hldgs (NASDAQ:IMCR), Allakos (NASDAQ:ALLK), AstraZeneca (NASDAQ:AZN), Merck & Co (NYSE:MRK), IMAC Holdings (NASDAQ:BACK), Arcutis Biotherapeutics (NASDAQ:ARQT), Adaptimmune Therapeutics (NASDAQ:ADAP), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) – Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary
[ad_1] The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ SPPI lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.…
Silence Therapeutics (NASDAQ:SLN), Alnylam Pharmaceuticals (NASDAQ:ALNY), Eli Lilly (NYSE:LLY), Amryt Pharma (NASDAQ:AMYT), SCYNEXIS (NASDAQ:SCYX), SINTX Technologies (NASDAQ:SINT), Ocuphire Pharma (NASDAQ:OCUP), Regeneron Pharmaceuticals (NASDAQ:REGN), VistaGen Therapeutics (NASDAQ:VTGN), Axsome Therapeutics (NASDAQ:AXSM), Lyra Therapeutics (NASDAQ:LYRA), Revance Therapeutics (NASDAQ:RVNC) – Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary
[ad_1] The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ RVNC lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines…
(VIRX) – Viracta Obtains Orphan Drug Status From European Commission For T-cell Lymphoma Candidate
[ad_1] The European Commission has granted an orphan drug designation (ODD) to Viracta’s VIRX lead drug combination nanatinostat and valganciclovir (Nana-val) for the treatment of peripheral T-cell lymphoma (PTCL). The…
(IMRX), Novavax (NVAX), (PYPD), Vertex Pharmaceuticals (VRTX) – Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
[ad_1] The U.S. Food and Drug Administration (FDA) has approved expanded use of Vertex’s VRTX lead asset ORKAMBI (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to <24…
(YMAB) – FDA Advisory Committee Scheduled For October 28, 2022 To Review Y-mAbs’ Refiling For Omburtamab
[ad_1] The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has been scheduled for October 28, 2022 to review Y-mAbs Therapeutics’ YMAB Biological License Application…